Search
Rebuilding the future for hematology in Ukraine today
The Hague (Netherlands), December 5, 2022 - Nearly 8 million Ukrainians have fled their country since February 24 according to the UN Refugee Agency, while about 5 million people have moved back.
Read moreEHA Research Conference 2022
Dates: October 17-20, 2022
Location: Palermo (Sicily), Italy
Chairs: Emmanuelle Passegué, Cristina Lo Celso, Mick Milsom, Meri Alberich Jorda, Antonella Fidanza, Jürg Schwaller, Thomas Mercher and Brian Huntly
Registration is closed
EHA is proud to announce the inaugural edition of the EHA Research Conference,…
EHA has joined the European Cancer Organisation - a perfect match on objectives and prioritization
The European Hematology Association (EHA) has joined the European Cancer Organisation, a not-for-profit federation of organizations working in cancer at the European level.
Read moreEHA’s advocacy for hematology continues
The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:
Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…
Chairs and Members
Chair
Edward Laane, Tartu University, Estonia (2022–2024)
Vice-Chair
Esther Natalie Oliva, Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Italy (2022–2024)
Sam Salek, University of Hertfordshire, United Kingdom (2022–2024)
Steering Committee
Tatiana Ionova, St.
EHA Innovation Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreAbstract & Clinical Case Submission
Abstract submission is an important part of the 7th European CAR T-cell Meeting.
Read morePomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- »